{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:12:34Z","timestamp":1793707954484,"version":"4.6.1"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Meningococcal disease (MD) remains a significant public health concern worldwide. In Serbia, mandatory immunization against MD with the meningococcal polysaccharide vaccine (MenAC) for high-risk groups and international travelers was introduced in 2006. Since 2017, the polysaccharide vaccine has been replaced with the quadrivalent meningococcal conjugate vaccine (MenACWY). The aim of this study was to analyze long-term trends in incidence, age-specific patterns, seasonality, and lethality of invasive meningococcal disease (IMD) in the Autonomous Province of Vojvodina (AP Vojvodina), Serbia, over a 28-year period. Methods: A descriptive study analyzed all reported cases of IMD in AP Vojvodina, from 1997 to 2024. Data were obtained from the regional communicable disease surveillance system, based on mandatory hospital reporting and case classification according to national and WHO guidelines. Temporal, demographic, and clinical characteristics, along with disease outcomes, were analyzed. Results: From 1997 to 2024, 175 IMD cases were reported in AP Vojvodina. The annual incidence peaked in 1997 (1.24\/100,000), with smaller surges in 2003 and 2005. Since 2006, coinciding with the introduction of immunization against MD, a sustained decline has been observed, with incidence rarely exceeding 0.30\/100,000. A slight resurgence occurred in 2023\u20132024, with 13 cases reported. From 1997 to 2024, IMD in AP Vojvodina exhibited a clear seasonal pattern, with most cases occurring in winter and early spring, peaking in January (17%), March (12%), and February (11%), and the fewest cases occuring in the summer months. Throughout the study period, the highest IMD incidence rates were consistently observed among infants &lt;1 year of age and children aged 1\u20134 years, with peaks of up to 22.9\/100,000 and 16.0\/100,000, respectively. Incidence was much lower in older age groups, especially adults. After a 2006 peak, rates declined across all ages, with a slight resurgence in 2023\u20132024 among children and adolescents. Children aged 1\u20134 years made up the largest share of IMD cases, peaking in January\u2013March (45.1%). Half of the infant cases were recorded in October\u2013November, while cases in older children, adolescents, and adults were fewer and showed varied monthly patterns, with small peaks in winter and early spring. During the 28-year study period, the highest IMD mortality rate was observed among infants &lt;1 year of age (0.59 per 100,000 population), followed by children aged 1\u20134 years (0.32 per 100,000). Mortality rates declined progressively with increasing age, with the lowest rate recorded among individuals aged \u226540 years (0.01 per 100,000). Of the 175 IMD cases reported in AP Vojvodina (1997\u20132024), 21 were fatal (case fatality rate [CFR] = 12.0%). The CFR of IMD varied across age groups. The highest CFR was observed among individuals aged \u226540 years (21.4%), followed by the 5\u20139 years (17.4%) and &lt;1 year (16.7%) age groups. None of the patients had been vaccinated against MD. Fatal outcomes were more common in children aged 1\u20134 years and among rural residents, though differences were not statistically significant (p &gt; 0.05). Most deaths (57.1%) occurred in the first quarter of the year. A strong association was found between clinical form and outcome, with meningococcal sepsis being significantly more frequently associated with fatality than meningitis (p = 0.0002). Deaths were sporadic over time, with most occurring within 1\u20132 days of notification. All confirmed fatal cases were due to serogroup B. Conclusions: MD remains a rare yet serious public health threat in AP Vojvodina. Mortality rates indicate that the public health impact of this disease is greatest among the youngest age groups; however, the risk of death, i.e., disease severity, does not appear to be age dependent. The recent rise in cases, high fatality among sepsis patients, and absence of prior vaccination among all IMD cases highlight the need for enhanced surveillance, physician education, and consideration of introducing both MenACWY and MenB vaccines for high-risk groups.<\/jats:p>","DOI":"10.3390\/vaccines13090945","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T09:18:57Z","timestamp":1756977537000},"page":"945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Twenty-Eight Years of Invasive Meningococcal Disease Surveillance in the Autonomous Province of Vojvodina, Serbia: Epidemiological Trends and Implications for Enhanced Surveillance and Vaccination Policy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-189X","authenticated-orcid":false,"given":"Mioljub","family":"Risti\u0107","sequence":"first","affiliation":[{"name":"Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia"},{"name":"Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-7825","authenticated-orcid":false,"given":"Vladimir","family":"Vukovi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia"},{"name":"Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Pustahija","sequence":"additional","affiliation":[{"name":"Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia"},{"name":"Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-9861","authenticated-orcid":false,"given":"Sne\u017eana","family":"Medi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia"},{"name":"Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9243-7522","authenticated-orcid":false,"given":"Gorana","family":"Dragovac","sequence":"additional","affiliation":[{"name":"Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia"},{"name":"Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia"},{"name":"Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2011). Meningococcal vaccines: WHO position paper, November 2011. Wkly. Epidemiol. Rec., 86, 521\u2013539."},{"key":"ref_2","unstructured":"Centers for Disease Prevention and Control (CDC) (2025, July 13). Chapter 8: Meningococcal Disease, Epidemiology and Prevention of Vaccine-Preventable Diseases, Available online: https:\/\/www.cdc.gov\/surv-manual\/php\/table-of-contents\/chapter-8-meningococcal-disease.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.html?utm_source=chatgpt.com."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.idc.2015.08.002","article-title":"The Changing Epidemiology of Meningococcal Disease","volume":"29","author":"Cohn","year":"2015","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1017\/S0950268823000328","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: A literature review","volume":"151","author":"Findlow","year":"2023","journal-title":"Epidemiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","article-title":"The epidemiology of meningococcal disease and the impact of vaccines","volume":"9","author":"Khatami","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/cid\/ciab791","article-title":"Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study","volume":"74","author":"Ohm","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2025, July 13). Invasive Meningococcal Disease-Annual Epidemiological Report for 2022, Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2022."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2214-109X(16)30064-X","article-title":"Seasonal dynamics of bacterial meningitis: A time-series analysis","volume":"4","author":"Paireau","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14760584.2023.2225596","article-title":"Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: A review of the available data","volume":"22","author":"Zografaki","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","unstructured":"Pravilnik o Imunizaciji i Na\u010dinu Zastite Lekovima (2025, July 15). Slu\u017ebeni Glasnik Republike Srbije, broj 11\/2006, 25\/2013, 63\/2013, 99\/2013, 118\/2013, 65\/2014, 32\/2015. (In Serbian)."},{"key":"ref_12","unstructured":"Pravilnik o Imunizaciji i Na\u010dinu Zastite Lekovima (2025, July 15). Slu\u017ebeni Glasnik Republike Srbije, broj 88\/2017, 11\/2018, 14\/2018, 45\/2018, 48\/2018, 58\/2018, 104\/2018, 6\/2021, 52\/2021 i 66\/2022. (In Serbian)."},{"key":"ref_13","unstructured":"Pravilnik o Programu Obavezne i Preporu\u010dene Imunizacije Stanovni\u0161tva Protiv Odre\u0111enih Zaraznih Bolesti (2025, July 15). Slu\u017ebeni Glasnik Republike Srbije, broj 65\/2020. (In Serbian)."},{"key":"ref_14","unstructured":"Institut za Javno Zdravlje Srbije \u201cDr Milan Jovanovi\u0107 Batut\u201d (2025). Stru\u010dno-Metodolo\u0161\u03bao Uputstvo Za Sprovo\u0111enje Obavezne I Preporu\u010dene Imunizacije Stanovni\u0161tva Za 2025. Godinu, Institut za javno zdravlje Srbije. (In Serbian)."},{"key":"ref_15","unstructured":"Statistical Office of the Republic of Serbia (2025, July 15). Census of Population, Households and Dwellings in the Republic of Serbia (1991, 2002, 2011, and 2022), (In Serbian)."},{"key":"ref_16","unstructured":"World Health Organization (2025, July 15). Meningococcus. Vaccine Preventable Diseases. Surveillance Standards. Available online: https:\/\/www.who.int\/publications\/m\/item\/vaccine-preventable-diseases-surveillance-standards-meningococcus."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Findlow, J., Htar, M.T.T., Villena, R., and Balmer, P. (2025). Invasive Meningococcal Disease in the Post-COVID World: Patterns of Disease Rebound. Vaccines, 13.","DOI":"10.3390\/vaccines13020165"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2301186","DOI":"10.1080\/21645515.2023.2301186","article-title":"Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?","volume":"20","author":"Tzanakaki","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"ref_20","unstructured":"Institute of Public Health of Vojvodina (2019). Communicable Diseases in Vojvodina, 2018, Institute of Public Health of Vojvodina. (In Serbian)."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(06)70466-2","article-title":"Interactions between influenza and bacterial respiratory pathogens: Implications for pandemic preparedness","volume":"6","author":"Brundage","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Poulikakos, P., Kapnisis, D., Xirogianni, A., Liakou, I., Tsolia, M., Michos, A., Mantadakis, E., Papaevangelou, V., Iliadis, A., and Gkentzi, D. (2025). Invasive Meningococcal Disease in Children: Outcomes and Risk Factors for Sequelae and Fatal Cases in Greece. Microorganisms, 13.","DOI":"10.3390\/microorganisms13040705"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: Clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2011.02.058","article-title":"The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease","volume":"29","author":"Harrison","year":"2011","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1286-4579(00)00356-7","article-title":"Epidemiology and pathogenesis of Neisseria meningitidis","volume":"2","author":"Tzeng","year":"2000","journal-title":"Microbes Infect."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Delic, S., Mijac, V., Gajic, I., Kekic, D., Ranin, L., Jegorovic, B., Culic, D., Cirkovic, V., Siljic, M., and Stanojevic, M. (2021). A Laboratory-Based Surveillance Study of Invasive Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae Diseases in a Serbian Pediatric Population-Implications for Vaccination. Diagnostics, 11.","DOI":"10.3390\/diagnostics11061059"},{"key":"ref_29","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2025, July 31). Vaccine Scheduler, Available online: https:\/\/vaccine-schedule.ecdc.europa.eu\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s43856-025-00800-2","article-title":"Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France","volume":"5","author":"Hong","year":"2025","journal-title":"Commun. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Taha, S., Terrade, A., Doucoure, O., Deghmane, A.E., and Taha, M.K. (2025). Troubled Times, Changing Tides: A Seroprevalence Study on Meningococcal Immunity in France Between 2016 and 2024. Vaccines, 13.","DOI":"10.3390\/vaccines13060647"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","article-title":"Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations","volume":"116","author":"Taha","year":"2022","journal-title":"Pathog. Glob. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","article-title":"First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England","volume":"73","author":"Ladhani","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.15585\/mmwr.mm7349a3","article-title":"New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, October 2024","volume":"73","author":"Schillie","year":"2024","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_35","unstructured":"World Health Organization (2021). Defeating Meningitis by 2030: A Global Road Map, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240026407."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:04Z","timestamp":1760035144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vaccines13090945"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13090945","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}